At what point during first-line treatment with mono-immunotherapy for oligometastatic NSCLC is the ideal time to consider consolidative radiation/SBRT to the primary and oligometastatic sites?

What I do in general first and foremost is judge whether or not it’s appropriate to offer consolidation: reasonable indications thus far have been: oligometastatic disease status at presentation, oligoprogressive disease after therapy, limited # of sites to irradiate, safe to deliver SBRT in the ana...

Agree with Dr Lee above. I see no reason why one cannot extrapolate from the Gomez data, which gave 3 months of targeted therapy (or 4 cycles platinum doublet chemo), assessed response, and treated non-progressors to the primary and oligomets